In the last trading session, 1.25 million Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) shares changed hands as the company’s beta touched -0.15. With the company’s per share price at $2.02 changed hands at $0.03 or 1.51% during last session, the market valuation stood at $94.09M. RVPH’s last price was a discount, traded about -139.11% off its 52-week high of $4.83. The share price had its 52-week low at $0.60, which suggests the last value was 70.3% up since then. When we look at Reviva Pharmaceuticals Holdings Inc’s average trading volume, we note the 10-day average is 1.59 million shares, with the 3-month average coming to 2.84 million.
Analysts gave the Reviva Pharmaceuticals Holdings Inc (RVPH) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RVPH as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Reviva Pharmaceuticals Holdings Inc’s EPS for the current quarter is expected to be -0.22.
Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) trade information
Instantly RVPH was in green as seen at the end of in last trading. With action 14.12%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 11.60%, with the 5-day performance at 14.12% in the green. However, in the 30-day time frame, Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) is 0.50% up. Looking at the short shares, we see there were 5.3 million shares sold at short interest cover period of 19.04 days.
Reviva Pharmaceuticals Holdings Inc (RVPH) estimates and forecasts
Data shows that the Reviva Pharmaceuticals Holdings Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 100.00% over the past 6 months, a 41.21% in annual growth rate that is considerably higher than the industry average of 17.30%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Reviva Pharmaceuticals Holdings Inc earnings to increase by 40.26%, but the outlook for the next 5-year period is at 20.47% per year.
RVPH Dividends
Reviva Pharmaceuticals Holdings Inc is expected to release its next quarterly earnings report in March.
Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 14.79% of Reviva Pharmaceuticals Holdings Inc shares while 30.07% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 35.28%. There are 30.07% institutions holding the Reviva Pharmaceuticals Holdings Inc stock share, with WOODLINE PARTNERS LP the top institutional holder. As of 2024-06-30, the company held 6.6273% of the shares, roughly 1.59 million RVPH shares worth $2.04 million.
MILLENNIUM MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 5.1656% or 1.24 million shares worth $1.59 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 700.44 shares estimated at $1.41 million under it, the former controlled 2.09% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.93% of the shares, roughly 312.3 shares worth around $0.63 million.
